The effect and mechanism of cabozantinib in the treatment of lung squamous cell carcinoma

Cabozantinib, as a multi-target tyrosine kinase inhibitor, has attracted much attention in cancer treatment in recent years.

In the treatment of lung squamous cell carcinoma, cabozantinib has shown certain efficacy. According to relevant studies, cabozantinib has an effective rate of 44% for RET-rearranged non-small cell lung cancer, including lung squamous cell carcinoma. In addition, studies have shown that in the late-line treatment of advanced lung cancer, cabozantinib can shrink tumors to varying degrees in 64% of patients. This data covers a variety of pathological types including lung squamous cell carcinoma. These findings indicate that cabozantinib has a certain effect in the treatment of lung squamous cell carcinoma.

The therapeutic mechanism of cabozantinib mainly involves its inhibitory effect on multiple tyrosine kinase targets. Specifically, cabozantinib can inhibit RET, MET, VEGFR-1/2/3, and KIT. , TRKB, FLT-3, AXL and TIE-2 and other targets. These targets are closely related to the occurrence and development of tumors, and involve many key processes such as tumor growth, metastasis, and angiogenesis.

In lung squamous cell carcinoma, these targets may be hyperactive, promoting tumor growth and spread. Cabozantinib blocks the signaling pathways of tumor cells by inhibiting the activity of these targets, thereby slowing down the growth and spread of tumor cells. This multi-target inhibitory effect makes cabozantinib highly effective in the treatment of lung squamous cell carcinoma.

Cabozantinib, as a multi-target inhibitor, has shown significant effects in the treatment of lung squamous cell carcinoma. By inhibiting the activity of multiple key targets, it interferes with key biological processes of cancer cells, thereby achieving therapeutic purposes. However, resistance to cabozantinib may also occur during treatment, requiring continued attention and adjustment of the treatment plan.